Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...

OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies ...

IDEFIRIX Product Sales Increased 83% Compared to the Prior Year LUND, Sweden, Feb. 6, 2025 /PRNewswire/ -- Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced ...

The company’s lead gene therapy, BV-702, is AAV-based and is in preclinical development ... aging-related diseases needs efficient delivery vectors. The greater payload of the CMV vector allows ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...